Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | BLM | P54132 | 2/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | GSR | P00390 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9856739 | 0.94 | BLM (0.76) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL1358872 | 0.92 | BLM (0.64) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL9856556 | 0.87 | ALDH1A1 (0.70) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Carmustine SCHEMBL2047318 | 0.85 | ALDH1A1 (1.00) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Carmustine SCHEMBL4503 | 0.85 | ALDH1A1 (1.00) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL9856783 | 0.85 | ALDH1A1 (0.68) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Elmustine SCHEMBL93476 | 0.84 | ALDH1A1 (0.82) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Carmustine SCHEMBL5783727 | 0.81 | ALDH1A1 (0.89) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL10005923 | 0.81 | ALDH1A1 (0.77) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL9856483 | 0.81 | ALDH1A1 (0.77) | ALDH1A1BLMPMP22MEN1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111202849-B | Albumin-bound nitrosourea antitumor pharmaceutical preparation and preparation method thereof | 四川大学 | 2022-06-03 | — | — | CN | claimed |
| CN-111202849-B | Albumin-bound nitrosourea antitumor pharmaceutical preparation and preparation method thereof | 四川大学 | 2022-06-03 | — | — | CN | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-20140140962-A1 | VIRUSES MODIFIED WITH UNNATURAL MOIETIES AND METHODS OF USE THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140086939-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-03-27 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8460708-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-06-11 | — | — | US | disclosed |
| US-20050187140-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050186244-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050182463-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182467-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182450-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182469-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050178396-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050175703-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050175665-A1 | In combination with antiscarring, antifibrotic, and antiinflammatory agents for preventing surgical adhesions, and cartilage loss; hypertrophic scars, keloids, arthritis, vascular disease; injection or topical administration | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187140-A1 | Polymer compositions and methods for their use | COL2A1, COL14A1, COL1A1 | ALDH1A1 1645/4885BLM 1186/4885PMP22 635/4885 |
| US-20050186244-A1 | Polymer compositions and methods for their use | COL2A1, COL14A1, COL1A1 | ALDH1A1 1645/4885BLM 1186/4885PMP22 635/4885 |
| US-20050175665-A1 | In combination with antiscarring, antifibrotic, and antiinflammatory agents for preventing surgical adhesions, and cartilage loss; hypertrophic scars, keloids, arthritis, vascular disease; injection or topical administration | MMP1, COL2A1, MMP13 | ALDH1A1 608/4885BLM 2452/4885PMP22 937/4885 |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | MMP1, COL2A1, FN1 | ALDH1A1 1677/4885BLM 3420/4885PMP22 2022/4885 |
| US-20050175703-A1 | Polymer compositions and methods for their use | COL2A1, COL14A1, COL1A1 | ALDH1A1 1645/4885BLM 1186/4885PMP22 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.